摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

十八烷酸辛酯 | 109-36-4

中文名称
十八烷酸辛酯
中文别名
——
英文名称
octyl stearate
英文别名
octyl octadecanoate;1-octyl stearate;n-octyl stearate;stearic acid octyl ester;Stearinsaeure-octylester;octylstearate
十八烷酸辛酯化学式
CAS
109-36-4
化学式
C26H52O2
mdl
——
分子量
396.698
InChiKey
IIGMITQLXAGZTL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    43-44 °C
  • 沸点:
    438.7±13.0 °C(Predicted)
  • 密度:
    0.860±0.06 g/cm3(Predicted)
  • LogP:
    11.994 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    11.9
  • 重原子数:
    28
  • 可旋转键数:
    24
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2915709000

SDS

SDS:b37c0badcffaa590e13ad071d7cb8993
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • TREATMENT FOR DISCOID LUPUS
    申请人:Magilavy Daniel
    公开号:US20120232106A1
    公开(公告)日:2012-09-13
    Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.
    I和II以及含有它们的盐和药物组合物可用于治疗皮肤疾病和/或障碍,例如皮肤红斑狼疮,例如急性皮肤红斑狼疮、亚急性皮肤红斑狼疮或盘状红斑狼疮。在某些实施例中,化合物以局部组合物形式提供。
  • CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
    申请人:Bapat Abhijit S.
    公开号:US20140364595A1
    公开(公告)日:2014-12-11
    The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.
    该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为:(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X,其中:AFA是抗真菌剂或抗菌剂;L是载体;X是连接剂;m范围从1到10;n范围从2到10;m′为1到10;p为1到10;n′为1到10;q为1到10,前提是q'和n不同时为1;m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外,该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
  • [EN] TRIAZINE DERIVATIVES AS UV ABSORBERS<br/>[FR] DERIVES DE LA TRIAZINE UTILISES COMME ABSORBANTS U.V.
    申请人:CIBA SC HOLDING AG
    公开号:WO2004064797A1
    公开(公告)日:2004-08-05
    The present invention relates to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently from each other are hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7,cycloalkyl; C1-C6alkylene-C5- C7,cycloalkyl; R9 is hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7cycloalkyl; C1-C6alkylene-C5-C7cycloalkyl; C6-C10aryl; A is-S-; -O- or -NR10-, wherein R10 has the same meanings as R9; X is COOR11; CONR12R13; SO3,R14; or SO2NR15R16, wherein R11, R12,R13, R14,R15, and R16, have independently from each other the same meanings as R9; to their preparation and to their use as UV absorbers in cosmetic and pharmaceutical formulations.
    本发明涉及公式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、R7和R8彼此独立地是氢;C1-C18烷基;C2-C18烯基;C5-C7环烷基;C1-C6烷基-C5-C7环烷基;R9是氢;C1-C18烷基;C2-C18烯基;C5-C7环烷基;C1-C6烷基-C5-C7环烷基;C6-C10芳基;A是-S-;-O-或-NR10-,其中R10具有与R9相同的含义;X是COOR11;CONR12R13;SO3R14;或SO2NR15R16,其中R11、R12、R13、R14、R15和R16彼此独立地具有与R9相同的含义;以及它们的制备和它们作为化妆品和药用配方中的紫外线吸收剂的用途。
  • TREATMENT FOR VITILIGO
    申请人:Rigel Pharmaceuticals, Inc.
    公开号:US20140073659A1
    公开(公告)日:2014-03-13
    Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
    I和II化合物以及前药、水合物、溶剂化物、N-氧化物、盐和含有它们的药物组合物可用于治疗白癜风。在某些实施方式中,化合物以局部组合物的形式提供。
  • BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
    申请人:SENOMYX, INC.
    公开号:US20160376263A1
    公开(公告)日:2016-12-29
    The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.
    本发明涵盖已知用于改变苦味感知的化合物和组合物,以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种:冷却剂;无活性药物成分;活性药用成分;食品添加剂或食品;调味剂或调味增强剂;食品或饮料产品;苦味化合物;甜味剂;苦味剂;酸味调味剂;咸味调味剂;鲜味调味剂;植物或动物产品;已知用于宠物护理产品中的化合物;已知用于个人护理产品中的化合物;已知用于家用产品中的化合物;制药制剂;局部制剂;大麻衍生或与大麻相关的产品;已知用于口腔护理产品中的化合物;饮料;香味、香水或除臭剂;已知用于消费品中的化合物;硅化合物;磨料;表面活性剂;发热剂;吸烟物品;脂肪、油脂或乳化剂;和/或益生菌或补充剂。
查看更多